Drug target validation and identification of secondary drug target effects using DNA microarrays

Matthew J. Marton, Joseph L. Derisi, Holly A. Bennett, Vishwanath R. Iyer, Michael R. Meyer, Christopher J. Roberts, Roland Stoughton, Julja Burchard, David Slade, Hongyue Dai, Douglas E. Bassett, Leland Hartwell, Patrick O. Brown, Stephen H. Friend

Research output: Contribution to journalArticle

565 Citations (Scopus)

Abstract

We describe here a method for drug target validation and identification of secondary drug target effects based on genome-wide gene expression patterns. The method is demonstrated by several experiments, including treatment of yeast mutant strains defective in calcineurin, immunophilins or other genes with the immunosuppressants cyclosporin A or FK506. Presence or absence of the characteristic drug 'signature' pattern of altered gene expression in drug-treated cells with a mutation in the gene encoding a putative target established whether that target was required to generate the drug signature. Drug dependent effects were seen in 'targetless' cells, showing that FK506 affects additional pathways independent of calcineurin and the immunophilins. The described method permits the direct confirmation of drug targets and recognition of drug-dependent changes in gene expression that are modulated through pathways distinct from the drug's intended target. Such a method may prove useful in improving the efficiency of drug development programs.

Original languageEnglish (US)
Pages (from-to)1293-1301
Number of pages9
JournalNature Medicine
Volume4
Issue number11
DOIs
StatePublished - Nov 1998
Externally publishedYes

Fingerprint

Microarrays
Oligonucleotide Array Sequence Analysis
DNA
Pharmaceutical Preparations
Immunophilins
Gene expression
Calcineurin
Tacrolimus
Gene Expression
Genes
Gene encoding
Immunosuppressive Agents
Yeast
Cyclosporine
Yeasts
Cells
Genome
Mutation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Marton, M. J., Derisi, J. L., Bennett, H. A., Iyer, V. R., Meyer, M. R., Roberts, C. J., ... Friend, S. H. (1998). Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature Medicine, 4(11), 1293-1301. https://doi.org/10.1038/3282

Drug target validation and identification of secondary drug target effects using DNA microarrays. / Marton, Matthew J.; Derisi, Joseph L.; Bennett, Holly A.; Iyer, Vishwanath R.; Meyer, Michael R.; Roberts, Christopher J.; Stoughton, Roland; Burchard, Julja; Slade, David; Dai, Hongyue; Bassett, Douglas E.; Hartwell, Leland; Brown, Patrick O.; Friend, Stephen H.

In: Nature Medicine, Vol. 4, No. 11, 11.1998, p. 1293-1301.

Research output: Contribution to journalArticle

Marton, MJ, Derisi, JL, Bennett, HA, Iyer, VR, Meyer, MR, Roberts, CJ, Stoughton, R, Burchard, J, Slade, D, Dai, H, Bassett, DE, Hartwell, L, Brown, PO & Friend, SH 1998, 'Drug target validation and identification of secondary drug target effects using DNA microarrays', Nature Medicine, vol. 4, no. 11, pp. 1293-1301. https://doi.org/10.1038/3282
Marton MJ, Derisi JL, Bennett HA, Iyer VR, Meyer MR, Roberts CJ et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature Medicine. 1998 Nov;4(11):1293-1301. https://doi.org/10.1038/3282
Marton, Matthew J. ; Derisi, Joseph L. ; Bennett, Holly A. ; Iyer, Vishwanath R. ; Meyer, Michael R. ; Roberts, Christopher J. ; Stoughton, Roland ; Burchard, Julja ; Slade, David ; Dai, Hongyue ; Bassett, Douglas E. ; Hartwell, Leland ; Brown, Patrick O. ; Friend, Stephen H. / Drug target validation and identification of secondary drug target effects using DNA microarrays. In: Nature Medicine. 1998 ; Vol. 4, No. 11. pp. 1293-1301.
@article{0c9b77c8e2cf400fa9b07b01a0234f91,
title = "Drug target validation and identification of secondary drug target effects using DNA microarrays",
abstract = "We describe here a method for drug target validation and identification of secondary drug target effects based on genome-wide gene expression patterns. The method is demonstrated by several experiments, including treatment of yeast mutant strains defective in calcineurin, immunophilins or other genes with the immunosuppressants cyclosporin A or FK506. Presence or absence of the characteristic drug 'signature' pattern of altered gene expression in drug-treated cells with a mutation in the gene encoding a putative target established whether that target was required to generate the drug signature. Drug dependent effects were seen in 'targetless' cells, showing that FK506 affects additional pathways independent of calcineurin and the immunophilins. The described method permits the direct confirmation of drug targets and recognition of drug-dependent changes in gene expression that are modulated through pathways distinct from the drug's intended target. Such a method may prove useful in improving the efficiency of drug development programs.",
author = "Marton, {Matthew J.} and Derisi, {Joseph L.} and Bennett, {Holly A.} and Iyer, {Vishwanath R.} and Meyer, {Michael R.} and Roberts, {Christopher J.} and Roland Stoughton and Julja Burchard and David Slade and Hongyue Dai and Bassett, {Douglas E.} and Leland Hartwell and Brown, {Patrick O.} and Friend, {Stephen H.}",
year = "1998",
month = "11",
doi = "10.1038/3282",
language = "English (US)",
volume = "4",
pages = "1293--1301",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Drug target validation and identification of secondary drug target effects using DNA microarrays

AU - Marton, Matthew J.

AU - Derisi, Joseph L.

AU - Bennett, Holly A.

AU - Iyer, Vishwanath R.

AU - Meyer, Michael R.

AU - Roberts, Christopher J.

AU - Stoughton, Roland

AU - Burchard, Julja

AU - Slade, David

AU - Dai, Hongyue

AU - Bassett, Douglas E.

AU - Hartwell, Leland

AU - Brown, Patrick O.

AU - Friend, Stephen H.

PY - 1998/11

Y1 - 1998/11

N2 - We describe here a method for drug target validation and identification of secondary drug target effects based on genome-wide gene expression patterns. The method is demonstrated by several experiments, including treatment of yeast mutant strains defective in calcineurin, immunophilins or other genes with the immunosuppressants cyclosporin A or FK506. Presence or absence of the characteristic drug 'signature' pattern of altered gene expression in drug-treated cells with a mutation in the gene encoding a putative target established whether that target was required to generate the drug signature. Drug dependent effects were seen in 'targetless' cells, showing that FK506 affects additional pathways independent of calcineurin and the immunophilins. The described method permits the direct confirmation of drug targets and recognition of drug-dependent changes in gene expression that are modulated through pathways distinct from the drug's intended target. Such a method may prove useful in improving the efficiency of drug development programs.

AB - We describe here a method for drug target validation and identification of secondary drug target effects based on genome-wide gene expression patterns. The method is demonstrated by several experiments, including treatment of yeast mutant strains defective in calcineurin, immunophilins or other genes with the immunosuppressants cyclosporin A or FK506. Presence or absence of the characteristic drug 'signature' pattern of altered gene expression in drug-treated cells with a mutation in the gene encoding a putative target established whether that target was required to generate the drug signature. Drug dependent effects were seen in 'targetless' cells, showing that FK506 affects additional pathways independent of calcineurin and the immunophilins. The described method permits the direct confirmation of drug targets and recognition of drug-dependent changes in gene expression that are modulated through pathways distinct from the drug's intended target. Such a method may prove useful in improving the efficiency of drug development programs.

UR - http://www.scopus.com/inward/record.url?scp=0031730097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031730097&partnerID=8YFLogxK

U2 - 10.1038/3282

DO - 10.1038/3282

M3 - Article

C2 - 9809554

AN - SCOPUS:0031730097

VL - 4

SP - 1293

EP - 1301

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 11

ER -